Business Wire Feed
Alchemer Research Reveals Gender Divide in Healthcare Satisfaction Priorities
2026 Healthcare Experience Report uncovers distinct drivers between men and women in trust, loyalty and retentionLOUISVILLE, Colo.--(BUSINESS WIRE)--New research from Alchemer, a global leader in customer experience and feedback technology, reveals a gender divide in more...
Belmont Village Senior Living Earns Eighth Great Place to Work® Certification, Reflecting a Culture Built on Trust and Purpose
HOUSTON--(BUSINESS WIRE)--Belmont Village Senior Living, a leading developer, owner, and operator of senior living communities across the U.S., has earned certification as a Great Place to Work® for the eighth time. The certification is awarded more...
Once Upon a Farm Releases 2025 Impact Report, Advancing Mission to Shape the Future of Food
Public Benefit Corporation and Certified B Corp advances mission to drive systemic change in childhood nutrition while supporting a healthier, more equitable food system 2025 Once Upon a Farm Impact Report Highlights: Expanded access to more...
Can Gen Z Men’s View of Mental Health Improve Workforce Retention and Productivity?
New research from The Standard reveals that more Gen Z men are taking mental health leave than men of any other generation in the workforce.PORTLAND, Ore.--(BUSINESS WIRE)--The Standard’s latest research, Mental Health in the Workplace: more...
Adaptyx Biosciences Presents First In-Human Continuous Multi-Day Free Cortisol Data From a Wearable Sensor at ADA, Providing a Time-resolved View of the Hormone Signal Driving Glucose Control, Cardiovascular Health, Stress Response, and Sleep
Late-breaking ADA data deliver two first in-human proof points: concordance between Adaptyx's wearable free-cortisol signal and paired venous blood measurements after a controlled oral hydrocortisone challenge, and continuous overnight monitoring of the body's own cortisol more...
Corsair Pharma Announces Three Presentations of Phase 1 Clinical Data for TRX-248 Transdermal System at the 2026 Pulmonary Hypertension Association Conference
Positive Phase 1 results demonstrate steady, continuous treprostinil exposure and support further clinical developmentNEWARK, Calif.--(BUSINESS WIRE)--Corsair Pharma, Inc., a private biopharmaceutical company, today announced three presentations related to its clinical program at the Pulmonary Hypertension more...
Amylyx Pharmaceuticals Announces Poster Presentations at ENDO 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--$AMLX--Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced two poster presentations at the upcoming Endocrine Society’s Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago, IL. The first more...
Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business
Seasoned healthcare executive with deep expertise in specialty pharmacy operations named Senior Vice President and General ManagerFORTH WORTH, Texas--(BUSINESS WIRE)--Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell” or the “Company”), a leading healthcare technology provider focused on empowering autonomous more...
Ignite Proteomics Announces Prospective 10,000-Patient Oncology Registry to Evaluate Functional Proteomics in Cancer Therapy Selection
Registry expected to pair Ignite’s reimbursed RPPA platform with structured outcomes tracking across ADC and immunotherapy regimens; initiative expected to generate an estimated ~$13 million for Ignite over the course of the agreementGOLDEN, Colo.--(BUSINESS WIRE)--Ignite more...
BostonGene to Present High-Impact AI Models and Biomarker-Driven Frameworks at EHA2026 Congress
Research highlights collaborative studies using predictive multiomics modeling to optimize risk stratification and predict treatment response in blood cancersWALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of the leading AI model for tumor and immune biology, today announced that more...
MediStreams Expands Reconciliation Solution Suite with New Ledger, Advanced Reporting, and Intelligent Matching Capabilities
New reconciliation capabilities to be demonstrated at the HFMA Annual ConferenceATLANTA--(BUSINESS WIRE)--#RCM--MediStreams, a leading provider of healthcare payment and remittance automation solutions, today announced significant enhancements to its Reconciliation solution suite, introducing a new Reconciliation more...
Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
New data from CATALYST and MOMENTUM trials presented at American Diabetes Association’s (ADA) 86th Scientific Sessions In the CATALYST trial, patients with hypercortisolism treated with Korlym exhibited clinically and statistically significant improvements in hemoglobin A1c more...
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
Dexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom G7 led more...
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide
Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3 low, medium and high dosing strategy VESPER-1 more...
Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care
STRIVE pivotal trial shows Omnipod 6 achieved strong glycemic outcomes with fewer boluses, across age groups and diabetes types EVOLUTION 3 feasibility study demonstrates improved time in range using a fully closed-loop system for type more...
Tidepool Showcases New Real-World Clinical Data and Landmark Women’s Health Initiative at ADA 2026
PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool, the nonprofit leader advancing innovation in diabetes technology, today unveiled new clinical insights and research initiatives in conjunction with the American Diabetes Association’s (ADA) 86th Scientific Sessions. The company’s presentation slate more...
OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions
Clinical data for TLC-6740 demonstrate additive metabolic benefits in combination with tirzepatide Novel preclinical findings for TLC-1180 demonstrate exercise-mimetic, insulin-sensitizing, and cognition-preserving effectsMENLO PARK, Calif.--(BUSINESS WIRE)--#ADA2026--OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company more...
New Study Reveals the True Environmental Impact of Periodontal Disease – And What You Can Do About It
Peer reviewed life cycle assessment published in the Journal of Dentistry (ISO 14040/14044-compliant) finds most impact comes from clinical care pathways, making prevention at home the biggest lever to improving outcomes for patients and the more...
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare Conference. Tempus Founder more...
CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 2026
New preclinical data demonstrate robust weight reduction, lean mass preservation, durable effects after treatment discontinuation and potential for extended dosing intervalsSHANGHAI--(BUSINESS WIRE)--CicadaBio today announced that new preclinical data for CC-18, its investigational GLP-1/anti-ActRII dual-pathway fusion more...
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate more...
Feinstein Institutes’ John M. Kane honored with 2026 Schizophrenia International Research Society Lifetime Achievement Award
Dr. Kane was recognized during the SIRS 2026 Annual Conference in Florence, ItalyMANHASSET, N.Y.--(BUSINESS WIRE)--John M. Kane, MD, co-director of the Institute of Behavioral Science at Northwell Health’s Feinstein Institutes for Medical Research, was awarded more...
IntraBio Announces Submission of Variation Application to the European Medicines Agency for AQNEURSA® for Ataxia-Telangiectasia
If approved, AQNEURSA® would become the first approved therapy for Ataxia-Telangiectasia in the European Economic AreaAUSTIN, Texas--(BUSINESS WIRE)--IntraBio Inc. today announced the submission of a variation application to the European Medicines Agency (EMA) to expand more...
TouchPoint Support Services Recognized as GenAI “Trailblazer” by Amazon Web Services
Recognition highlights TouchPoint’s leadership in applying AI to transform healthcare support servicesATLANTA--(BUSINESS WIRE)--TouchPoint Support Services was recently named a GenAI “Trailblazer” by Amazon Web Services (AWS) for the creation of TouchPointGPT, an AI-powered chatbot powered more...
Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy
SAN DIEGO--(BUSINESS WIRE)--$TNDM #TandemMobi--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of CE mark for expanded indications of its automated insulin delivery (AID) systems in Europe. more...